Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13539465 | 0.79 | CYP2D6 (0.48) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 | |
| SCHEMBL11100471 | 0.79 | CYP2D6 (0.48) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 | |
| SCHEMBL11192903 | 0.79 | CYP2D6 (0.48) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 | |
| SCHEMBL4331801 | 0.79 | TSHR (0.46) | CYP2D6TSHRCYP2C19HSD17B10CYP3A4 | |
| SCHEMBL14154663 | 0.78 | KCNN4 (0.41) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 | |
| SCHEMBL28790233 | 0.75 | TSHR (0.42) | CYP2D6TSHRCYP2C19HSD17B10CYP3A4 | |
| SCHEMBL8733990 | 0.75 | CYP1A2 (0.42) | CYP2D6TSHRCYP2C19HSD17B10ADRA2C | |
| SCHEMBL89308 | 0.72 | KCNN4 (0.44) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 | |
| SCHEMBL15434945 | 0.72 | KCNN4 (0.44) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL16685140 | 0.72 | ALOX15 (0.42) | CYP2D6TSHRCYP2C19HSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-216484121-U | Chlorine ephedrine is sampling device for qualitative and quantitative inspection | 福建警察学院 | 2022-05-10 | — | — | CN | claimed |
| EP-1854160-A2 | REDOX-ACTIVE STRUCTURES AND DEVICES UTILIZING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2007-11-14 | — | — | EP | claimed |
| WO-2006085319-A2 | REDOX-ACTIVE STRUCTURES AND DEVICES UTILIZING THE SAME | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2006-08-17 | — | — | WO | claimed |
| CN-115272710-B | Method, equipment and medium for rapidly detecting drugs based on photonic crystal image | 公安部物证鉴定中心 | 2026-02-17 | — | — | CN | disclosed |
| US-20230321281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | FTGEN Corp | 2023-10-12 | — | — | US | disclosed |
| CN-116615552-A | Compositions and methods for treating ocular disorders | 方拓生物科技公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116323949-A | Compositions and methods for treating ocular disorders | 方拓生物科技公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4185319-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | Frontera Therapeutics, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-216484121-U | Chlorine ephedrine is sampling device for qualitative and quantitative inspection | 福建警察学院 | 2022-05-10 | — | — | CN | disclosed |
| WO-2019154948-A1 | TAMPER RESISTANT FORMULATION OF EPHEDRINE AND ITS DERIVATIVES COMPRISING A CONVERSION INHIBITOR | Grünenthal GmbH (DE) | 2019-08-15 | — | — | WO | disclosed |
| US-20190247332-A1 | TAMPER RESISTANT FORMULATION OF EPHEDRINE AND ITS DERIVATIVES COMPRISING A CONVERSION INHIBITOR | Grünenthal GmbH (DE) | 2019-08-15 | — | — | US | disclosed |
| EP-1854160-A2 | REDOX-ACTIVE STRUCTURES AND DEVICES UTILIZING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2007-11-14 | — | — | EP | disclosed |
| EP-1833468-A1 | TABLET FORMULATION FOR SUSTAINED DRUG-RELEASE | UNIVERSITE DE MONTREAL (CA) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006085319-A2 | REDOX-ACTIVE STRUCTURES AND DEVICES UTILIZING THE SAME | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006066399-A1 | TABLET FORMULATION FOR SUSTAINED DRUG-RELEASE | UNIVERSITE DE MONTREAL (CA) | 2006-06-29 | — | — | WO | disclosed |
| EP-0665744-B1 | STABLE EXTENDED RELEASE ORAL DOSAGE COMPOSITION | SCHERING CORP (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0665744-A1 | STABLE EXTENDED RELEASE ORAL DOSAGE COMPOSITION | SCHERING CORPORATION (US) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994009761-A1 | STABLE EXTENDED RELEASE ORAL DOSAGE COMPOSITION | SCHERING CORPORATION (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0326278-B1 | METHOD FOR THE MANUFACTURE OF DRUG PERMEABLE MATERIALS | Dow Corning Kabushiki Kaisha (JP) | 1992-04-08 | — | — | EP | disclosed |
| EP-0326278-A1 | Method for the manufacture of drug permeable materials | Dow Corning Kabushiki Kaisha (JP) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247332-A1 | TAMPER RESISTANT FORMULATION OF EPHEDRINE AND ITS DERIVATIVES COMPRISING A CONVERSION INHIBITOR | TAAR1, MCHR1, TACR1 | CYP2D6 221/4885TSHR 303/4885CYP2C19 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.